(Q43172648)

English

Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide

scientific article published on 4 February 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 November 2017

Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide (English)

1 reference

Europe PubMed Central

15 November 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Estelle Watson

1

1 reference

Europe PubMed Central

15 November 2017

Daniël M Jonker

2

1 reference

Europe PubMed Central

15 November 2017

Lisbeth V Jacobsen

3

1 reference

Europe PubMed Central

15 November 2017

Steen H Ingwersen

4

1 reference

Europe PubMed Central

15 November 2017

publication date

4 February 2010

1 reference

Europe PubMed Central

15 November 2017

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

15 November 2017

50

1 reference

Europe PubMed Central

15 November 2017

8

1 reference

Europe PubMed Central

15 November 2017

886-894

1 reference

Europe PubMed Central

15 November 2017

Biology of incretins: GLP-1 and GIP

1 reference

https://api.crossref.org/works/10.1177%2F0091270009354996

21 January 2018

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

https://api.crossref.org/works/10.1177%2F0091270009354996

21 January 2018

Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects

1 reference

https://api.crossref.org/works/10.1177%2F0091270009354996

21 January 2018

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

1 reference

https://api.crossref.org/works/10.1177%2F0091270009354996

21 January 2018

Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness

1 reference

https://api.crossref.org/works/10.1177%2F0091270009354996

21 January 2018

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

1 reference

https://api.crossref.org/works/10.1177%2F0091270009354996

21 January 2018

An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide.

1 reference

https://api.crossref.org/works/10.1177%2F0091270009354996

21 January 2018

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

1 reference

https://api.crossref.org/works/10.1177%2F0091270009354996

21 January 2018

Effect of renal impairment on the pharmacokinetics of exenatide

1 reference

https://api.crossref.org/works/10.1177%2F0091270009354996

21 January 2018

Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors

1 reference

https://api.crossref.org/works/10.1177%2F0091270009354996

21 January 2018

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1177%2F0091270009354996

21 January 2018

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F0091270009354996

21 January 2018

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F0091270009354996

21 January 2018

A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4).

1 reference

https://api.crossref.org/works/10.1177%2F0091270009354996

21 January 2018

Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment

1 reference

https://api.crossref.org/works/10.1177%2F0091270009354996

21 January 2018

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F0091270009354996

21 January 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1177%2F0091270009354996

21 January 2018

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F0091270009354996

21 January 2018

Identifiers

10.1177/0091270009354996

1 reference

Europe PubMed Central

15 November 2017

1 reference

Europe PubMed Central

15 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43172648&oldid=2144453711"